RemeGen Co., Ltd. (HKG:9995)

Market Cap	71.70B +92.3%
Revenue (ttm)	3.84B +76.8%
Net Income	1.47B
EPS	2.65
Shares Out	559.97M
PE Ratio	31.54
Forward PE	13.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,662,471
Open	85.75
Previous Close	84.75
Day's Range	83.10 - 87.20
52-Week Range	61.65 - 126.60
Beta	0.45
Analysts	Buy
Price Target	116.47 (+39.15%)
Earnings Date	Aug 25, 2026

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops p...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 3,048
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9995

Financial Performance

Financial numbers in CNY

Analyst Summary

According to 15 analysts, the average rating for 9995 stock is "Buy." The 12-month stock price target is $116.47, which is an increase of 39.15% from the latest price.

Price Target

$116.47

(39.15% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 11, 2026

Data Sources Report a data error